Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver disease
Biotech
BioVie plans $20M IPO for spinout developing liver disease drug
BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved low blood pressure drug to market.
James Waldron
Mar 17, 2026 5:18am
Alfasigma's $690M deal for GSK itch drug awaiting FDA decision
Mar 9, 2026 6:55am
OrsoBio hits target in midstage study for metabolic conditions
Feb 10, 2026 8:00am
After $4.8B Amicus buy, BioMarin drops genetic disease asset
Dec 22, 2025 11:12am
GSK picks 1st biotech partners under $7B Flagship pact
Nov 20, 2025 6:30am
Aldeyra drops and swaps RASP assets in response to data
Oct 28, 2025 9:10am
